| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Monday, July 9, 2018 Several heart drugs containing valsartan are being recalled in Europe and Asia after a Chinese active ingredient manufacturer found residues of a substance in its supplies that could cause cancer. |
|
|
Top Stories Of The Week Thursday, July 12, 2018 Novartis is the latest big pharma player to decide that developing new anti-infectives isn’t on its priority list. Monday, July 9, 2018 President Donald Trump has taken aim at the largest U.S. drugmaker for price hikes. Trump's tweet comes only days after reports that Pfizer raised prices on dozens of drugs starting in July, with many increases coming in at 9%. Friday, July 6, 2018 A phase 2 Alzheimer’s trial—once nearly consigned to the heap of disappointing attempts against the disease—has re-emerged with new positive results, showing that an anti-amyloid beta protofibril antibody can slow clinical symptom decline, as well as reduce the accumulation of plaque in the brain. Wednesday, July 11, 2018 Pfizer’s shaking itself up again with some moves that put its branded drug business in charge of two big challenges: biosimilars, which need brand-level attention, and injectable hospital drugs, now beset by manufacturing woes. And with consumer health going solo, that leaves a generics business with “substantial autonomy.” Could a spinoff be next? Monday, July 9, 2018 T-cell therapies have generated enthusiasm because of their high response rates in patients with lymphoma and leukemia, but the technology has proven difficult to translate to solid tumors. MIT researchers have developed nanoparticles with drug payloads that enhance the cells' tumor-killing power without causing off-target effects. Tuesday, July 10, 2018 Cel-Sci has emerged victorious in what it describes as the first-ever decision in favor of a pharmaceutical company over a CRO for breach of contract, following a yearslong arbitration battle with inVentiv Health, now known as Syneos Health. Wednesday, July 11, 2018 Otsuka Pharmaceutical plans to acquire previous Fierce 15 winner Visterra and its antibody engineering platform for $430 million in cash, as Otsuka looks to build out proprietary drug discovery and development efforts across its programs, including in nephrology and other difficult diseases. Monday, July 9, 2018 Dermira has piqued consumer curiosity about sweat, thanks to an unbranded awareness campaign that laid the groundwork for its Qbrexza launch. Now that push is paying off, thanks to TV ads driving traffic to its branded website—and laying the groundwork for sales representatives it’s hiring now. Tuesday, July 10, 2018 In a string of bizarre events that involve violence, lawsuits and a high-profile investment shop, Nasdaq-listed Chinese vaccine maker Sinovac has terminated its plan to take the company private and instead accepted private investments worth $86.7 million. Resources Sponsored by: Veeva See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs). Sponsored by: Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. |
|
